Homa Pharmed

What Homa Pharmed does

Homa Pharmed Pharmaceutical Company is an Iranian pharmaceutical manufacturer founded in 2008 and headquartered in Tehran, Iran. The company initially operated as an importer of branded medicines before pivoting into manufacturing, building a GMP-certified production capability on a 12,000 m² campus equipped with Class A cleanrooms. Its manufacturing scope covers four specialized injectable formats: lyophilized injectables, terminally sterilized injectables, hazardous powder injectables, and pre-filled syringes, indicating a platform approach to sterile injectable production rather than a single-product operation.

The company organizes its portfolio around four therapeutic verticals — oncology, infertility, gynecology, aesthetics, and endocrinology — with named product lines including Zhoabex (a five-SKU dermal filler range for facial aesthetics), Karma (fertility injectables: Karma-FSH, Karma-HCG, Karma-HMG), Sandosphere LAR (an octreotide formulation for endocrine disorders), and Microrelin (triptorelin for endocrine and oncology indications). Regulatory certifications disclosed include cGMP, GMP-PIC/S, GMP-WHO, ICH Q10, and ISO 9001, suggesting the facility has been qualified against both domestic and international standards.

Homa Pharmed operates a B2B pharmaceutical go-to-market, engaging directly with specialist physicians and pharmacists rather than through broad retail channels. The reported professional network of 400+ specialist doctors and 70+ pharmacists indicates a relationship-led sales model concentrated in specialty care. The company has publicly signaled an international expansion strategy targeting API manufacturing, oncology, and medical devices with a MENA regional focus, and was active at industry events such as Iran Pharma 2025.

Name

Homa Pharmed

Legal name

Homa Pharmed Pharmaceutical Company

Website

https://homapharmed.com

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

51–100 employees

Short description

Homa Pharmed is an Iranian pharmaceutical manufacturer founded in 2008, producing GMP-certified injectable products across oncology, fertility, endocrinology, and aesthetics therapeutic areas. The company operates a 12,000 m² manufacturing facility and sells B2B to healthcare professionals in the MENA region.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

akta.pro secondary industries

Women’s Health & Reproductive Specialty Pharmaceuticals (HLAIACAN), Endocrinology & Metabolic Specialty Pharmaceuticals (HLAIACAD), Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH)

Keywords

• Injectable pharmaceuticals
• Oncology therapeutics
• Fertility treatments
• Dermal fillers
• Biopharmaceutical manufacturing

Headquarters

HQ city

Tehran

HQ country

Iran

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Pharmaceutical Product Sales: Sale of specialized injectable pharmaceutical products across oncology, infertility, gynecology, aesthetics, and endocrine therapeutic areas

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Homa Pharmed is a pharmaceutical manufacturer that develops, produces, and sells injectable pharmaceutical products across four main therapeutic areas: oncology, fertility and reproductive medicine, endocrinology, and aesthetic medicine. The company operates a GMP-certified manufacturing plant producing lyophilized products, terminal sterilized injectables, hazardous powder formulations, and pre-filled syringes, and sells branded products such as the Zhoabex dermal filler line, Sandosphere LAR (octreotide), Microrelin (triptorelin), and the Karma fertility hormone range (FSH, HCG, HMG).

Product overview

Homa Pharmed is a pharmaceutical company offering a diverse portfolio of injectable products across four main therapeutic areas: aesthetics (Zhoabex line of dermal fillers including VOLUME, DEEP, SOFT TOUCH, LIGHT LINES, and LIPS variants), fertility (Karma-FSH, Karma-HCG, and Karma-HMG hormone-based treatments), endocrinology (Sandosphere LAR octreotide formulations at 20mg and 30mg, and Microrelin triptorelin formulations at 3.75mg and 11.25mg), and oncology. The company operates a GMP-certified manufacturing facility producing injectable pharmaceuticals including lyophilized products, and maintains a patient support unit for treatment guidance.

Differentiator

Problem solved

Functional benefit

Brands

• Zhoabex: Dermal filler product line including VOLUME, DEEP, SOFT TOUCH, LIGHT LINES, and LIPS variants for aesthetic applications.
• Sandosphere LAR
• Microrelin
• Karma-FSH
• Karma-HCG
• Karma-HMG

Products and services

• Zhoabex VOLUME Dermal filler product for soft tissue augmentation, part of the Zhoabex aesthetic product line, used by aesthetic medicine practitioners.
• Zhoabex DEEP Dermal filler for deeper tissue injection, part of the Zhoabex aesthetic product line.
• Zhoabex SOFT TOUCH Dermal filler designed for soft tissue augmentation with a lighter formulation, part of the Zhoabex line.
• Zhoabex LIGHT LINES Dermal filler designed for fine lines and subtle aesthetic enhancements, part of the Zhoabex line.
• Zhoabex LIPS Dermal filler specifically formulated for lip augmentation, part of the Zhoabex aesthetic line.
• Sandosphere LAR 30 mg Octreotide 30 mg long-acting release injectable for endocrine and oncology applications.
• Sandosphere LAR 20 mg Octreotide 20 mg long-acting release injectable for endocrine disorders.
• Microrelin 11.25 mg Triptorelin Acetate 11.25 mg formulation used in hormonal disorders and oncology indications.
• Microrelin 3.75 mg Triptorelin Acetate 3.75 mg formulation used for hormonal suppression in oncology and endocrinology.
• Karma-FSH Follicle-stimulating hormone (FSH) injectable for fertility treatments, used by reproductive medicine specialists.
• Karma-HCG Human chorionic gonadotropin (HCG) injectable for fertility treatments.
• Karma-HMG Human menopausal gonadotropin (HMG) product combining HMG-FSH-HCG for fertility treatments.

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• Sanofi: Global pharmaceutical company with established franchises in fertility, endocrinology (including triptorelin originator Decapeptyl and oncology adjacencies), and specialty injectables. Represents the large incumbent against which Homa Pharmed's Microrelin and Karma lines compete therapeutically.
• Hikma Pharmaceuticals: Jordan-headquartered multinational pharmaceutical company with significant injectable and specialty pharma operations across MENA and the US. Larger established incumbent with overlapping injectable manufacturing capabilities and MENA market presence.

Direct peers

• Ferring Pharmaceuticals: Global specialty pharmaceutical company focused on reproductive health, endocrinology, and urology. Direct therapeutic overlap with Homa Pharmed's Microrelin (triptorelin), Karma fertility line, and Sandosphere (octreotide) franchises.
• Darou Pakhsh Pharmaceutical (DPPC): One of Iran's largest domestic pharmaceutical manufacturers producing injectables, oral solids, and biologics across oncology and specialty care. Closest direct competitor to Homa Pharmed in branded injectable specialty pharma within Iran.
• CinnaGen: Iranian biotech company specializing in biosimilars and biological medicines including fertility hormones and oncology biologics. Directly comparable to Homa Pharmed's Karma fertility line and biological drug development focus.
• Spimaco Addwaeih: Saudi Arabian pharmaceutical manufacturer producing branded generics and specialty products across MENA. Comparable regional peer serving similar hospital and specialty pharma channels in the GCC.
• Julphar (Gulf Pharmaceutical Industries): UAE-headquartered MENA pharmaceutical manufacturer producing injectables, oral solids, and specialty products with significant regional export footprint. Closest regional peer operating GMP-certified injectable manufacturing in the MENA region.
• Actoverco: Iranian pharmaceutical manufacturer producing injectables, tablets, and sterile products with focus on women's health and specialty therapeutic areas. Comparable Iranian specialty injectable peer.
• Tolid Daru (TPICO): Iranian pharmaceutical company manufacturing a broad portfolio of branded and generic injectables and oral dosage forms. Comparable domestic manufacturer operating GMP facilities serving similar therapeutic segments.
• Barakat Pharmaceutical: Iranian pharmaceutical company producing specialty and generic medicines across women's health, oncology, and fertility. Domestic peer operating in overlapping therapeutic categories within Iran.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/homapharmed

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Homa Pharmed